NMDA activation plays an important role in learning and memory. NMDA receptors were found to decrease in the frontal lobe and hippocampus of Alzheimer's disease and mild cognitive function impairment. This study is a randomized, double-blind, placebo-controlled drug trial. All patients will be allocated randomly to 2 groups: (1) NMDA enhancer: DAOI-B group (starting dose: 250-500 mg/d); (2) placebo group. The study period is 24 weeks. The investigators hypothesize that DAOI-B may yield better efficacy than placebo for cognitive function in patients with mild cognitive impairment or mild Alzheimer's disease.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
86
250-1500 mg/day, oral, for 24 weeks
placebo, oral, for 24 weeks
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung, Taiwan, Taiwan
Change from baseline in Alzheimer's disease assessment scale-cognitive subscale in week 8, 16 and 24
Time frame: Week 0, 8, 16, 24
Change from baseline in Mini Mental Status Examination at week 8, 16 and 24
Time frame: Week 0, 8, 16, 24
Change from baseline in Instrumental Activities of Daily Living at week 8, 16 and 24
Time frame: Week 0, 8, 16, 24
Change from baseline in Verbal learning and memory at week 24
Time frame: Week 0, 24
Change from baseline in Digit Span subtest of the Wechsler Memory Scale at week 24
Time frame: Week 0, 24
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.